The Impact of the Indonesian Chronic Disease Management Program (PROLANIS) on Metabolic Control and Renal Function of Type 2 Diabetes Mellitus Patients in Primary Care Setting

• Main Authors: Firas Farisi Alkaff (Author), Fauzan Illavi (Author), Sovia Salamah (Author), Wiwit Setiyawati (Author), Ristra Ramadhani (Author), Elly Purwantini (Author), Dicky L. Tahapary (Author)
• Format: Book
• Published: SAGE Publishing, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2150-1327; 10.1177/2150132720984409
• Keywords: Computer applications to medicine. Medical informatics; R858-859.7; Public aspects of medicine; RA1-1270
• Source: Journal of Primary Care & Community Health, Vol 12 (2021)

Background: Indonesia through its government National Health Insurance System has launched a non-communicable and chronic disease management program named Indonesian Chronic Disease Management Program (PROLANIS), with Type 2 Diabetes Mellitus (T2DM) and hypertension as the main focus. However, study that evaluates the clinical impact of PROLANIS in patients with T2DM is still scarce to this date. This study aims to evaluate the metabolic control and renal function of PROLANIS participants with T2DM every six month within the first 18-months of implementation. Methods: This study was a retrospective cohort study conducted at Wates sub-district, East Java using secondary data from PROLANIS group report from April 2018 to October 2019. The study population was T2DM patients who voluntarily joined the PROLANIS group in April 2018. The six-month-evaluation included metabolic parameters [body mass index (BMI), blood pressure, hemoglobin A1C, total cholesterol, high-density lipid, low-density lipid, and triglyceride (TG)] and renal parameters [blood urea nitrogen (BUN), creatinine serum, and urinary microalbumin]. Paired t -test and wilcoxon signed-rank test was used for the analysis, and the P -value was adjusted using Bonferroni correction. A P -value < .0015 was considered statistically significant, while a P -value between .0015 and .003 was considered as marginally significant. Results: A total of 30 participants were included in the analysis. Following the PROLANIS implementation, the only parameter of metabolic control that showed significant improvement was TG serum level ( P < .001). Despite the worsening status of other metabolic parameters, the changes were not statistically significant except for BMI that was marginally significant ( P = .002). From renal function, only BUN serum level was significantly deteriorated ( P < .001), while the others did not significantly change. Conclusion: PROLANIS implementation in our study population seems to be ineffective. Future study with more primary healthcare centers needs to be done to scrutinize the clinical impact of this program nationwide.